Chiwata, Masahiko; Itonaga, Hidehiro; Sato, Shinya; Hashimoto, Miki; Fujioka, Machiko; Kasai, Sachie; Sakamoto, Hikaru; Toriyama, Eo; Nakashima, Jun; Kamijo, Rena; Kitanosono, Hideaki; Kobayashi, Yuji; Horai, Makiko; Taguchi, Masataka; Matsuo, Masatoshi; Makiyama, Junya; Takasaki, Yumi; Matsuo, Emi; Horio, Kensuke; Ando, Koji; Sawayama, Yasushi; Taguchi, Jun; Kawaguchi, Yasuhisa; Tsushima, Hideki; Imanishi, Daisuke; Imaizumi, Yoshitaka; Yoshida, Shinichiro; Jo, Tatsuro; Nonaka, Hiroaki; Moriuchi, Yukiyoshi; Nagai, Kazuhiro; Yokota, Ken-ichi; Hata, Tomoko; Miyazaki, Yasushi published an article in 2021, the title of the article was Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: a report from the Nagasaki CML study group.Category: piperazines And the article contains the following content:
The standard treatment for chronic myeloid leukemia (CML) is the continuous use of tyrosine kinase inhibitors (TKIs), which results in a favorable prognosis for the majority of patients. Recent studies have identified cardiovascular diseases (CVDs) as late adverse events (AEs) related to TKIs. In this study, we evaluated the long-term efficacy and AEs of TKIs, focusing on CVDs. We performed a retrospective survey of CML patients (diagnosed from 2001 to 2016) treated with TKIs in Nagasaki Prefecture. Clin. data were obtained from their medical records. We analyzed the survival, estimated cumulative incidence of CVDs, and risk factors for CVD among CML patients treated with TKIs. The overall survival rate of 264 CML patients treated with TKIs (median age 58 years old) was 89.6% [95% confidence interval (CI), 84.9-92.9%], and 80.5% (95% CI, 73.4-85.9%) at 5 and 10 years after the CML diagnosis, resp. CVD events occurred in 26 patients (9.8%, median age 67.5 years old) with a median 65.5 mo of TKI treatment. The cumulative incidences at 2 and 5 years was 2.4% (95% CI, 1.0-4.8%) and 5.2% (95% CI, 2.8-8.6%), resp. Hypertension and a high SCORE chart risk at the diagnosis of CML were associated with CVD events during TKI treatment. TKI treatment contributed to the long-term survival of CML patients in Nagasaki Prefecture in a “real-world” setting, but the incidence of CVDs seemed to be increased in these patients. A proper approach to managing risk factors for CVD is warranted to reduce CVD events during TKI treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines
The Article related to cardiovascular adverse event tki treatment efficacy chronic myeloid leukemia, adverse event, cardiovascular disease, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Category: piperazines
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics